Moderna, Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Direxion Daily Semiconductor Bull 3X Shares trades at $139.85 (market cap $24.42B). The key difference: Moderna, Inc. is far larger — about 3.2× Direxion Daily Semiconductor Bull 3X Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Direxion Daily Semiconductor Bull 3X Shares for 15 Days on average.
| MRNA | SOXL | |
|---|---|---|
Market Cap | $78.65B | $24.42B |
Volume | 37,373,437 | 100,232,380 |
Sector | Health | Leveraged / Inverse |
52-Week High | $203.46 | $300.77 |
52-Week Low | $22.36 | $30.81 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $74.80B | — |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $139.3, down 12.34% in the last 24 hours amid semiconductor sector volatility. Technical indicators show a bearish overall signal with mixed moving averages and neutral oscillators. The fund's leveraged structure amplifies both gains and losses in the semiconductor sector, which faces conflicting signals from strong AI demand versus concerns about valuation and regulatory risks.
The outlook for SOXL remains highly volatile, with opportunities tied to sustained AI-driven semiconductor demand but significant risks from the fund's 3x leverage structure and sector-specific headwinds. Investors face amplified exposure to semiconductor stock fluctuations, requiring careful risk management given the current bearish technical setup and mixed market sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →